Linagliptin (Trajenta)
DPP-4 inhibitor · DPP-4 class · oral smd · Boehringer Ingelheim
Top dose
5 mg
HbA1c reduction
-0.69%
at week 24 · efficacy
AE discontinuation
2.5%
Status
approved
Pivotal trial
- Trial
- Monotherapy (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 24 weeks
- ClinicalTrials.gov
- NCT00328172
- Sponsor
- Boehringer Ingelheim
Notes
Trajenta (co-marketed by Boehringer Ingelheim and Lilly): the DPP-4 with no renal dose adjustment. HbA1c ~-0.7%, weight-neutral, CV-neutral (CARMELINA / CAROLINA).